102 related articles for article (PubMed ID: 10470214)
1. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
Wolff JM; Fandel TH; Borchers H; Jakse G
Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
Wolff JM; Fandel T; Borchers H; Brehmer B; Jakse G
Br J Urol; 1998 Mar; 81(3):403-5. PubMed ID: 9523660
[TBL] [Abstract][Full Text] [Related]
3. Tissue polypeptide specific antigen serum concentrations in patients with newly diagnosed prostatic diseases.
Wolff JM; Rohde D; Borchers H; Jakse G
Anticancer Res; 2000; 20(6D):5003-5. PubMed ID: 11326658
[TBL] [Abstract][Full Text] [Related]
4. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin markers in patients with prostatic diseases.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Anticancer Res; 1999; 19(4A):2649-52. PubMed ID: 10470212
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
[TBL] [Abstract][Full Text] [Related]
7. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
8. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
Trapeznikova MF; Shibaeva AN; Ianshin AA; Urenkov SB; Mironova OS; Kazantseva IA; Kushlinskiĭ NE
Urologiia; 2004; (1):17-21. PubMed ID: 15022438
[TBL] [Abstract][Full Text] [Related]
9. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
10. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
[TBL] [Abstract][Full Text] [Related]
11. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
13. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
17. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
18. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
19. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
20. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]